Chemours is trading 6.68% up at $16.12, with the move appearing primarily recovery-oriented rather than tied to a confirmed fresh catalyst.
- Shares fell 18.63% on August 5, then gained 3.56% on August 6.
- Latest earnings coverage cited second-quarter revenue and adjusted EPS misses, weaker third-quarter EBITDA guidance, and RBC Capital lowering its price target to $22 while maintaining an outperform rating.
- No new August 7 company announcement clearly explains the intraday rebound.